AUREA Trial’s Decisive 90 Days: DAPT Shows Advantage Over OAC in Cerebral Protection post-TAVI?
EuroIntervention, an official Journal of Euro PCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), recently shareda post on X:
”In this randomized trial, OAC did not outperform DAPT in preventing cerebral microembolism post-TAVI. DW-MRI findings suggest DAPT may lead to lower total embolic volume at 90 days.”
Read the article here.
EuroInterention recently shared the AUREA trial data on use of OAC and DAPT: ‘A comparison of antiplatelet and oral anticoagulation strategies to prevent cerebral microembolism after transcatheter aortic valve implantation: the AUREA trial‘ published by Victor Alfonso Jimenez Diaz et al.
In the AUREA randomized clinical trial evaluating post-TAVI antithrombotic strategies, oral anticoagulation (OAC) did not outperform dual antiplatelet therapy (DAPT) in preventing cerebral microembolism.
Among patients without a formal indication for anticoagulation, a 3-month OAC regimen failed to demonstrate benefit over DAPT in reducing subclinical brain infarcts.
Diffusion-weighted MRI at 90 days revealed a lower mean embolic volume in patients receiving DAPT compared to those on acenocoumarol, suggesting DAPT may offer superior cerebral protection in this population.
Hemostasis Today, daily news on stroke management.
-
Feb 25, 2026, 16:47Alan Nurden: Platelet Defects Explain Bleeding in EHDS Patients
-
Feb 25, 2026, 16:40Mohammed Almohammadi: Uniting Leaders in Laboratory Hematology at the 1st Saudi ISLH Joint Conference
-
Feb 25, 2026, 16:37Salihu Asimawu: Inflammation Is Not a Disease – Hats Off to the Heroes Inside Us
-
Feb 25, 2026, 16:34Michael Makris: Biomarin Has Decided to Withdraw Roctavian from the Market
-
Feb 25, 2026, 16:25Tagreed Alkaltham: The Blood Banker Personality
-
Feb 25, 2026, 16:17Sanjay Ahuja: Insightful Talk on 100 Years of VWD by Jorge Di Paola
-
Feb 25, 2026, 15:20Michael Shapiro։ Creating Real Pathways for Trainees in Preventive Cardiology
-
Feb 25, 2026, 15:15Ajay Kumar: Plasma Component Quality Control Standards
-
Feb 25, 2026, 15:09Wolfgang Miesbach: Efficacy, Safety and Thrombosis Signals in Haemophilia A/B with Inhibitors